BASIC AND CLINICAL STUDIES ON CEFDINIR
スポンサーリンク
概要
- 論文の詳細を見る
We investigated fundamental and clinical studies on cefdinir (CFDN).<BR>1. Antibacterial activity: The MICs of CFDN against clinically isolated organisms were measured and compared with those of cefaclor (CCL), cephalexin (CEX) and ampicillin (ABPC). Against <I>Staphylococcus aureus</I>, the antibacterial activity of CFDN was equal or superior to that of ABPC and was superior to that of CCL and CEX by 3 and 4 dilution steps, respectively. Against <I>Escherichia coil, Klebsiella pneumoniae</I> and <I>Proteus mirabilis</I>, CFDN was more active than CCL by 2 to 3 and CEX by 5 to 7 steps. CCL, CEX and ABPC were inactive against <I>Proteus vulgris</I> and <I>Morganella morganii</I>, but CFDN had potent antibacterial activity. CFDN was superior to CCL, CEX and ABPC against <I>Serratia marcescens</I>. However, MICs were ≤12.5μg/ml in only 33% of the strains.<BR>2. Clinical study: CFDN was given to 39 patients;29 with pneumonia, 2 with acute bronchitis, 6 with acute exacerbation of chronic respiratory tract infections, 1 with acute tonsillitis and 1 with acute pharyngitis.<BR>The efficacy rates of CFDN were 79% in pneumonia, 80% in acute exacerbation of chronic respiratory tract infections and 100% in acute bronchitis, acute tonsillitis and acute pharyngitis. CFDN showed high clinical response with an efficacy rate of 82%. There was no difference in clinical efficacy in pneumonia betweeen the 300 mg/day and 600 mg/day groups. Bacteriologically, of three strains of <I>Streptococcus Pneumoniae</I>, one was eradicated, one was replaced by <I>Alcaligenes Faecalis</I> and one persisted. One of <I>Haemophilus influenzae</I> persisted, one of <I>E. coli</I> was eradicated and one of <I>Pseudomonas aeruginosa</I> was unknown. The bacteriological eradication rate, including replaced strains, was 60%.<BR>As to side effects, diarrhea plus abdominal pain and nausea developed in one patient each, but subsided the day after withdrawal of CFDN. No abnormal laboratory findings were noted in any of the cases.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.